Patient Medication Information: uses, side effects, how to take - NRA-Ezetimibe

What the medication is used for:

NRA-Ezetimibe helps to reduce the amount of cholesterol and triglycerides in your blood in conjunction with lifestyle changes including exercise, diet, and weight management, when a response to such changes has been inadequate.

Cholesterol is one of several fatty substances found in the bloodstream. Your total cholesterol is made up mainly of low-density lipoprotein cholesterol and high density lipoprotein cholesterol (LDL and HDL cholesterol).

LDL cholesterol is often called “bad” cholesterol because it can build up in the walls of your arteries forming plaque. Eventually this plaque build-up can lead to a narrowing of the arteries. This narrowing can slow or block blood flow to vital organs such as the heart and brain. This blocking of blood flow can result in a heart attack or stroke.

HDL cholesterol is often called “good” cholesterol because it helps keep the bad cholesterol from building up in the arteries and protects against heart disease.

Triglycerides are another form of fat in your blood that may increase your risk for heart disease.

NRA-Ezetimibe may be taken alone or with other cholesterol-lowering medicines known as statins or with another medicine known as fenofibrate, in addition to diet and other lifestyle changes (see INTERACTIONS WITH THIS MEDICATION). Ezetimibe adds to the cholesterol- lowering effect of statins and fenofibrate. Statins and fenofibrate lower cholesterol in a different way; they work in the liver.

What it does:

NRA-Ezetimibe works by decreasing the absorption of cholesterol in the small intestine.

When it should not be used:

Patients who are hypersensitive (allergic) to ezetimibe or any of the nonmedicinal ingredients should not take NRA-Ezetimibe.

Patients with liver disease, active or unexplained increases in liver enzymes (blood tests of liver function) should not take NRA-Ezetimibe together with a statin.

Patients who are pregnant should not take NRA- EZETIMIBE together with a statin.

Patients who are nursing should not take NRA- EZETIMIBE together with a statin.

What the medicinal ingredient is:

Ezetimibe.

What the important nonmedicinal ingredients are: Croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone K-30, polysorbate 80 and sodium lauryl sulfate.

What dosage forms it comes in:

Tablet 10 mg (white to off-white, capsule-shaped, flat faced with beveled edge, uncoated tablets, debossed with “10” on one side and plain on other side).

Before you use NRA-Ezetimibe talk to your doctor if you:

are pregnant, plan to become pregnant or think you might be pregnant.

are breast-feeding. Ezetimibe may be passed in your milk to your baby.

have now or have had in the past any medical problems (including liver disease or liver problems).

You should always tell your doctor about all drugs that you are taking or plan to take as well as those obtained without a prescription.

Drugs that may interact with ezetimibe include:

Cyclosporine

Cholestyramine (a resine/bile acid sequestrant) or any other bile acid sequestrant. In that case, NRA- EZETIMIBE should be taken at least 2 hours before or 4 hours after taking the bile acid sequestrant.

Fibrates

IMPORTANT: PLEASE READ

ABOUT THIS MEDICATION

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Liver disease (Hepatitis) Pancreas disease (Pancreatitis)

Muscle pain (Myopathy/Rhabdomyolysis, myalgia) Severe allergic reaction (Anaphylaxis)

INTERACTIONS WITH THIS MEDICATION

PROPER USE OF THIS MEDICATION

Usual dose:

NRA-Ezetimibe should be taken as directed.

Take one 10 mg tablet by mouth each day, preferably at the same time of day. NRA- EZETIMIBE can be taken with or without food.

Continue taking your other cholesterol-lowering medicines known as statins or fenofibrate unless your doctor tells you to stop.

If you are taking a statin or fenofibrate, NRA- EZETIMIBE can be taken at the same time.

Even if you are taking medication to treat high cholesterol, it is important to have your cholesterol measured regularly. You should also know your cholesterol levels and goals.

Overdose:

Take NRA-Ezetimibe only as prescribed for you. If you take more NRA-Ezetimibe than you were prescribed, contact your doctor or pharmacist.

Missed dose:

If you miss a dose, just resume the usual schedule of one tablet daily.

reported: raised red rash, sometimes with target-shaped lesions; dizziness; depression; tingling sensation; constipation; and unusual tiredness or weakness

You should contact your doctor if you develop persistent and severe muscle aches or pains with no obvious explanation at any time after starting to take NRA- EZETIMIBE.

If you are prescribed NRA-Ezetimibe with a statin, your doctor will order routine blood tests to check your liver function before and after starting treatment.

Talk to your doctor anytime you have a medical problem you think may be related to NRA-Ezetimibe.

NRA-Ezetimibe tablets are generally well tolerated.

When used alone, the following common side effects have been reported: abdominal pain; diarrhea; flatulence; tiredness; viral infection; throat infection (pharyngitis); nose infection (sinusitis); joint pain (arthralgia); back pain; and coughing.

The following uncommon side effects have been reported: elevations in some laboratory blood tests of liver (transaminases) or muscle (CK) function; indigestion; heartburn; nausea; muscle spasms; neck pain; decreased appetite; hot flush; high blood pressure; chest pain and pain.

When used with a statin, the following common side effects have been reported: headache; tiredness; abdominal pain; diarrhea; joint pain (arthralgia); muscle pain (myalgia); back pain; throat infection (pharyngitis); nose infection (sinusitis); upper chest infection (respiratory tract); and changes in certain laboratory blood tests.

The following uncommon side effects have been reported: tingling sensation; dry mouth; gastritis; itching; rash; hives; muscular weakness; pain in arms and legs; unusual tiredness or weakness; and swelling, especially in the hands and feet.

When used with fenofibrate, the following side effect was reported: abdominal pain

In general use, the following side effects have been

This is not a complete list of side effects. For any unexpected effects while taking NRA-Ezetimibe, contact your doctor or pharmacist.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom / effect		Talk with your healthcare professional				Stop taking drug and get immediate medical help
		Only if severe		In all cases
Rare	Muscle aches and pains (Myopathy/ Rhabdomyolysis)		√
	Sudden severe allergic reactions (swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing, rash and hives).						√
	Symptoms of liver problems (severe abdominal pain, especially if felt on the upper right side below the ribs, dark urine, general itchiness, severe nausea or vomiting, pale stools, yellowing of skin or eyes)				√
	Symptoms of gallstones or inflammation of the gallbladder (severe abdominal pain, nausea, vomiting)				√
	Symptoms of pancreas problems (severe abdominal pain)				√

IMPORTANT: PLEASE READ

If you think you have taken too much NRA-Ezetimibe, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Keep your medicine between 15°C and 30°C. Protect from moisture.

Keep NRA-Ezetimibe and all medicines out of the reach and sight of children.

Do not use this medicine after the date shown following EX (or EXP) on the container.

If you want more information about NRA-Ezetimibe:

Talk to your healthcare professional
Find the full product monograph that is prepared for healthcare professionals and includes this Consumer Information by visiting the Health Canada website (https://health-products.canada.ca/dpd-bdpp/index-eng.jsp); or by calling the sponsor Nora Pharma Inc. at 1-888-270-9874.

Nora Pharma Inc.,

1565, boul. Lionel-Boulet

Varennes, QC, J3X 1P7

Last revised: OCT 28, 2022